Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Primary cutaneous CD30+ T-cell lymphoma responsive to topical imiquimod (AldaraR)
Biagio Didona, Roberto Benucci, Paolo Amerio, et al.
British Journal of Dermatology (2004) Vol. 150, Iss. 6, pp. 1198-1201
Closed Access | Times Cited: 45

Showing 1-25 of 45 citing articles:

EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma*
Werner Kempf, Katrin Pfaltz, Maarten H. Vermeer, et al.
Blood (2011) Vol. 118, Iss. 15, pp. 4024-4035
Open Access | Times Cited: 392
Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy
Erika Vacchelli, Lorenzo Galluzzi, Alexander Eggermont, et al.
OncoImmunology (2012) Vol. 1, Iss. 6, pp. 894-907
Open Access | Times Cited: 224
Immunomodulation of the Tumor Microenvironment: Turn Foe Into Friend
Hanne Locy, Sven de Mey, Wout de Mey, et al.
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 212
Imiquimod in dermatology: an overview
Edith Hanna, Rami Abadi, Ossama Abbas
International Journal of Dermatology (2016) Vol. 55, Iss. 8, pp. 831-844
Closed Access | Times Cited: 177
In situ vaccination: Cancer immunotherapy both personalized and off‐the‐shelf
Linda Hammerich, Adam Binder, Joshua Brody
Molecular Oncology (2015) Vol. 9, Iss. 10, pp. 1966-1981
Open Access | Times Cited: 159
In Situ Vaccination for the Treatment of Cancer
Linda Hammerich, Nina Bhardwaj, Holbrook E. Kohrt, et al.
Immunotherapy (2016) Vol. 8, Iss. 3, pp. 315-330
Closed Access | Times Cited: 84
Enhancing immune responses to tumor-associated antigens
Jack P. Higgins, M. Bernstein, James W. Hodge
Cancer Biology & Therapy (2009) Vol. 8, Iss. 15, pp. 1440-1449
Open Access | Times Cited: 61
Anaplastic Large-Cell Lymphoma, T-/Null-Cell Type
Eric D. Jacobsen
The Oncologist (2006) Vol. 11, Iss. 7, pp. 831-840
Open Access | Times Cited: 64
Current management of primary cutaneous CD30+ T-cell lymphoproliferative disorders.
Marshall E. Kadin
PubMed (2009) Vol. 23, Iss. 13, pp. 1158-64
Closed Access | Times Cited: 49
Advances in the use of topical imiquimod to treat dermatologic disorders
Giuseppe Micali
Therapeutics and Clinical Risk Management (2008) Vol. Volume 4, pp. 87-97
Open Access | Times Cited: 40
Expression of functional toll-like receptors by B-chronic lymphocytic leukemia cells
Cindy Grandjenette, Anne Kennel, G Fauré, et al.
Haematologica (2007) Vol. 92, Iss. 9, pp. 1279-1281
Open Access | Times Cited: 40
Use of topical immunomodulators in organ transplant recipients
Bradley T. Kovach, Thomas Stasko
Dermatologic Therapy (2005) Vol. 18, Iss. 1, pp. 19-27
Closed Access | Times Cited: 37
Primary cutaneous CD30+ lymphoproliferative disorders: new insights into biology and therapy.
Christiane Querfeld, Timothy M. Kuzel, Joan Guitart, et al.
PubMed (2007) Vol. 21, Iss. 6, pp. 689-700,
Closed Access | Times Cited: 32
New and Experimental Skin-Directed Therapies for Cutaneous Lymphomas
Árpád Farkas, Lajos Kemény, Lars E. French, et al.
Skin Pharmacology and Physiology (2009) Vol. 22, Iss. 6, pp. 322-334
Open Access | Times Cited: 27
Practical Management of CD30+ Lymphoproliferative Disorders
Lauren C. Hughey
Dermatologic Clinics (2015) Vol. 33, Iss. 4, pp. 819-833
Open Access | Times Cited: 19
Clinical and laboratory experience of vorinostat (suberoylanilide hydroxamic acid) in the treatment of cutaneous T-cell lymphoma
Madeleine Duvic, C‐N Zhang
British Journal of Cancer (2006) Vol. 95, Iss. S1, pp. S13-S19
Open Access | Times Cited: 29
Efforts to Counteract Locally the Effects of Systemic Immunosupression: A Review on the Use of Imiquimod, a Topical Immunostimulator in Organ Transplant Recipients
Myrto Trakatelli, Georgios Katsanos, Claas Ulrich, et al.
International Journal of Immunopathology and Pharmacology (2010) Vol. 23, Iss. 2, pp. 387-396
Open Access | Times Cited: 22
CD30-Positive Lymphoproliferative Disorders
Liana Nikolaenko, Jasmine Zain, Steven T. Rosen, et al.
Cancer treatment and research (2018), pp. 249-268
Closed Access | Times Cited: 14
Treatment of primary cutaneous CD30+ anaplastic large cell lymphoma with intralesional methotrexate
Jonathan E. Blume, Howard L. Stoll, Richard T. Cheney
Journal of the American Academy of Dermatology (2006) Vol. 54, Iss. 5, pp. S229-S230
Closed Access | Times Cited: 18
Standard and experimental therapy in cutaneous T‐cell lymphomas
Reinhard Dummer, Antonio Cozzio, Sibylle Meier, et al.
Journal of Cutaneous Pathology (2006) Vol. 33, Iss. s1, pp. 52-57
Closed Access | Times Cited: 18
Successful treatment of primary cutaneous follicle centre lymphoma with topical 5% imiquimod
Anastasios Stavrakoglou, V.L. Brown, Ian Coutts
British Journal of Dermatology (2007) Vol. 157, Iss. 3, pp. 620-622
Closed Access | Times Cited: 15
Innovative Therapy of Cutaneous T-Cell Lymphoma: Beyond Psoralen and Ultraviolet Light and Nitrogen Mustard
Brian Poligone, Peter Heald
Dermatologic Clinics (2010) Vol. 28, Iss. 3, pp. 501-510
Open Access | Times Cited: 11
Cutaneous Anaplastic Large-Cell Lymphoma Should be Evaluated for Systemic Involvement Regardless of ALK-1 Status
Sherry Yang, Pooja Khera, Christina Wahlgren, et al.
American Journal of Clinical Dermatology (2011) Vol. 12, Iss. 3, pp. 203-209
Closed Access | Times Cited: 9
Long‐term remission of primary cutaneous neutrophil‐rich CD30+ anaplastic large cell lymphoma treated with topical imiquimod. A case report
Donato Calista, Luca Riccioni, Laura Bagli, et al.
Journal of the European Academy of Dermatology and Venereology (2015) Vol. 30, Iss. 5, pp. 899-901
Closed Access | Times Cited: 8
Toll-like receptor 2, 4, 7 and 9 expression in primary cutaneous CD30+ T-cell lymphoma
Anne‐Chantal Knol, Benjamin D. Ehst, A. Dompmartin, et al.
British Journal of Dermatology (2009) Vol. 161, Iss. 6, pp. 1414-1416
Closed Access | Times Cited: 9
Page 1 - Next Page

Scroll to top